PDF Cover

Loncastuximab Tesirine Market

The market for Loncastuximab Tesirine was estimated at $145 million in 2024; it is anticipated to increase to $252 million by 2030, with projections indicating growth to around $401 million by 2035.

Report ID:DS1804022
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Biotechnology
Loncastuximab Tesirine
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Loncastuximab Tesirine Market Outlook

Revenue, 2024

$145M

Forecast, 2034

$365M

CAGR, 2025 - 2034

9.7%

The Loncastuximab Tesirine industry revenue is expected to be around $158.7 million in 2025 and expected to showcase growth with 9.7% CAGR between 2025 and 2034. The Loncastuximab Tesirine market is experiencing growth due to the increasing occurrence of diffuse large B cell lymphoma and follicular lymphoma cases that require the use of Loncastuximab Tesirine for effective treatment outcomes as reported in studies. Moreover the widespread use of this medication, in healthcare settings globally and its ongoing clinical trials have solidified its importance in the sector and boosted its market presence. The rise of groundbreaking treatments like immunotherapy and progress, in biotechnology are essential factors fuel the remarkable growth of this market.

Loncastuximab Tesirine, also known as Zynlonta, is an antibody drug combination created for treating lymphomas and others of cancer that express CD19 proteins. It functions by pinpoint targeting cancer cells and delivering toxins to induce cell death. This treatment has revolutionized oncology due, to its effectiveness and fewer side effects when compared to standard chemotherapy methods.

Loncastuximab Tesirine market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Loncastuximab Tesirine Market Outlook

Market Key Insights

  • The Loncastuximab Tesirine market is projected to grow from $144.7 million in 2024 to $365 million in 2034. This represents a CAGR of 9.7%, reflecting rising demand across Lymphoma, Hematological Disorder, and Leukemia.

  • ADC Therapeutics SA is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Loncastuximab Tesirine market and are expected to observe the growth CAGR of 7.1% to 10.2% between 2024 and 2030.

  • Emerging markets including India, Mexico and Brazil are expected to observe highest growth with CAGR ranging between 9.3% to 12.1%.

  • The complete eco-system of the Loncastuximab Tesirine market is becoming more attractive for investment due to transitions such as Oncology Pharmaceutical Innovation. These changes are expected to create a positive cycle that supports growth and adds an estimated $14 million in value between 2025 and 2030.

  • The Loncastuximab Tesirine market is set to add $221 million between 2024 and 2034, with manufacturer targeting Specialty Clinics & Cancer Research Institutes Application projected to gain a larger market share.

  • With

    advancements in targeted cancer therapies, and

    Favorable Regulatory Support, Loncastuximab Tesirine market to expand 152% between 2024 and 2034.

loncastuximab tesirine market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Loncastuximab Tesirine - Country Share Analysis

Opportunities in the Loncastuximab Tesirine

Recent progress in the field of biotechnology has also created opportunities, for the advancement of cutting edge immunotherapies. The incorporation of state of the art solutions has the potential to enhance the effectiveness and safety of Loncastuximab Tesirine delivery methods and contribute to market expansion.

Growth Opportunities in North America and Europe

In North America's market for Loncastuxmab Tesirine is experiencing growth due to a thriving healthcare industry and the rising occurrence of lymphoma and other cancers treatable with Loncastuxmab Tesirine. The regions advanced healthcare facilities and supportive government regulations have made it an appealing market for this medication. Competition is intense here with top multinational pharmaceutical companies competing for dominance, in the market. In today's environment in North America's healthcare sector​, the success of Loncastuximab Tesirine hinges on proactive research and development activities and well timed product introductions that shape market leadership​. Factors like rising healthcare spending and growing interest, in cancer therapies also drive the market growth of this treatment option.
In the way Europe has a large portion of the worldwide market for Loncastuximab Tesirine product as well. This region has a healthcare network, strong financial ability and a population makeup that includes many elderly people. A group more vulnerable to variouss of cancer. These factors contribute to an increased demand for Loncastuximsab Tesirine in Europe. Moreover in the market there is fierce competition, with major pharmaceutical companies constantly striving to set their products apart through innovation. The market is also driven by factors like cancer research initiatives tailored to countries and a rising number of cancer cases along with a strong preference, for cutting edge therapies.

Market Dynamics and Supply Chain

01

Driver: Increasing Incidence of B‑Cell Malignancies and Innovation in Antibody‑Drug Conjugate Technologies

One major driver for loncastuximab tesirine is also the rising global incidence of B‑cell lymphomas and related hematological cancers, such as diffuse large B‑cell lymphoma (DLBCL), which increases the pool of eligible patients for targeted therapies like Zynlonta. Aging populations and greater disease detection through improved diagnostics contribute to higher case volumes each year. A related growth factor is also technological advancement in antibody‑drug conjugate (ADC) platforms, which enable precise delivery of potent cytotoxins directly to tumor cells expressing CD19, improving efficacy and reducing off‑target toxicity. Loncastuximab tesirine also represents a next‑generation ADC with a PBD dimer payload and stable linker chemistry that enhances tumor cell kill rates and clinical responses. These innovations encourage oncologists to adopt CD19‑targeted ADCs in relapsed or refractory settings and stimulate pipeline development for combination regimens to improve outcomes in heavily pretreated patients.
A key market driver for loncastuximab tesirine is also the growing trend in biomarker‑driven combination therapy development, where ADCs like Zynlonta are also paired with other agents to enhance therapeutic benefits. Clinical research such as the LOTIS‑7 and LOTIS‑5 trials explores combinations of loncastuximab with bispecific antibodies or rituximab to improve response rates and overcome resistance seen in relapsed or refractory cases. These niche strategies align with personalized oncology paradigms that leverage genetic and molecular profiling to tailor complex regimens, potentially expanding loncastuximab’s use beyond monotherapy and increasing its adoption among hematologists treating aggressive B‑cell malignancies.
02

Restraint: High Competition from Alternative Therapies and Clinical Trial Setbacks Reducing Market Momentum

A key restraint for loncastuximab tesirine is intense competition from emerging cancer treatments like CAR-T cell therapies, bispecific antibodies, and other ADCs, which can limit its adoption and market share in relapsed/refractory B‑cell malignancies. Such competitive pressure has contributed to modest uptake in its initial relapsed diffuse large B‑cell lymphoma niche and continues to influence physician treatment choices and payer preferences. Additionally, discontinuation of certain clinical trials, such as the Phase 2 LOTIS‑9 regimen for unfit or frail patients due to benefit‑risk concerns, highlights challenges in expanding indications and improves alternative regimens’ appeal, dampening future revenue growth and dampening long‑term market dynamics.
03

Opportunity: Exploiting Untapped Segments and Strategic Collaborations

According to market studies there is an opportunity for Loncastuximab Tesirine to grow in untapped markets. This includes focusing on increased marketing and distribution in areas with levels of lymphoma like certain regions in North America and Europe where the use of Loncastuximab Tesirine could be essential, for treatment.
In the competitive field of pharmaceuticals industry forming strategic partnerships and collaborations is crucial for expanding market presence and growth potential of Loncastuximab Tesirine could see positive outcomes through partnering with bigger pharmaceutical firms for cutting edge research and development activities along, with global distribution networks.
04

Challenge: Pricing and Reimbursement Constraints Limiting Broad Adoption and Revenue Expansion

Another significant restraint for loncastuximab tesirine is pricing and reimbursement pressure, which restricts access and demand. As a targeted antibody‑drug conjugate, Zynlonta carries substantial cost, prompting healthcare payers to negotiate discounts, impose utilization controls, or reserve coverage for narrowly defined patient segments. Market penetration has been modest, with adoption rates initially low and gradual, partly due to payer hesitancy to reimburse high‑cost therapies without robust real‑world evidence or expanded indications. Such economic constraints can slow revenue growth and limit usage in broader hematologic oncology settings, particularly outside major markets.

Supply Chain Landscape

1

Raw Materials Acquisition

Lonza GroupCatalent
2

Cell Processing & Manufacturing

ADC Therapeutics
3

Packaging & Distribution

CatalentFisher Clinical Services
4

End Users & Applications

LymphomaHematological Disorder
Loncastuximab Tesirine - Supply Chain

Use Cases of Loncastuximab Tesirine in Lymphoma & Leukemia

Lymphoma : Loncastuximab tesirine is principally used as an intravenous antibody‑drug conjugate for the treatment of relapsed or refractory large B‑cell lymphoma and high‑grade B‑cell lymphoma in adult patients who have failed at least two prior systemic therapies. Oncology specialists administer loncastuximab tesirine for its targeted mechanism of action, as it binds to the CD19 antigen on malignant B cells and delivers a potent cytotoxic agent directly into the tumor cells. This targeted approach enhances tumor cell death while sparing healthy tissues, improving outcomes in difficult‑to‑treat lymphoma cases where traditional chemotherapy has limited effectiveness.
Hematological Disorder : In broader hematological disorder management, loncastuximab tesirine is employed when conventional treatments are ineffective, particularly in aggressive B‑cell malignancies that are part of blood cancer spectrums. As a CD19‑directed therapy, it addresses the underlying biology of B‑cell derived disorders by delivering its cytotoxic payload directly to diseased cells, which is crucial for patients with relapsed or refractory disease after multiple treatment lines. Hematologists value its antibody‑drug conjugate technology because it combines specificity with potent DNA‑damaging activity, reducing systemic toxicity compared to non‑targeted chemotherapies and offering a valuable option in precision hematologic oncology care.
Leukemia : Loncastuximab tesirine is also being explored in leukemia, particularly for relapsed or refractory B‑cell acute lymphoblastic leukemia (B‑ALL) and other CD19‑expressing leukemic conditions. Although not yet a widely approved indication like lymphoma, early clinical studies show promise for its use in adult leukemia patients who have exhausted standard chemotherapy options. By targeting the CD19 protein expressed on leukemic B cells and delivering a cytotoxic pyrrolobenzodiazepine agent, loncastuximab tesirine may offer an effective treatment pathway with targeted cell killing and improved tolerability compared to traditional systemic therapies, especially in heavily pretreated individuals with few alternatives.

Recent Developments

Recent developments for loncastuximab tesirine reflect its evolving role in targeted oncology and ADC therapy. Expansion of clinical trials evaluating combinations with immunotherapies and bispecific antibodies highlights efforts to improve outcomes in relapsed or refractory B‑cell lymphoma. A key market trend is the shift toward precision cancer treatments supported by biomarker‑guided patient selection, which increases demand for CD19‑targeted therapies and companion diagnostics. Enhanced manufacturing capacity and regulatory approvals in additional regions are strengthening global uptake and competitive positioning within hematologic oncology.

December 2024 : ADC Therapeutics announced that it completed enrollment in the Phase 3 LOTIS‑5 confirmatory trial evaluating ZYNLONTA with rituximab for relapsed or refractory DLBCL. This milestone supports potential expanded indication in 2L+ patients and could enable regulatory submission upon topline results.
May 2024 : ADC Therapeutics reported that the LOTIS‑7 study of ZYNLONTA in combination with bispecific antibodies (glofitamab or mosunetuzumab) cleared final dosing and initiated dose expansion, bolstering clinical development for broader NHL indications.

Impact of Industry Transitions on the Loncastuximab Tesirine Market

As a core segment of the Biotechnology industry, the Loncastuximab Tesirine market develops in line with broader industry shifts. Over recent years, transitions such as Oncology Pharmaceutical Innovation and Market Competitiveness have redefined priorities across the Biotechnology sector, influencing how the Loncastuximab Tesirine market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Oncology Pharmaceutical Innovation

Loncastuxumab Tesirine represents a groundbreaking shift in the perspective and management of cancer within the realm of oncology treatments It signifies a departure from chemotherapy towards Antibody Drug Conjugates providing precise and efficient therapies, with reduced toxicity levels The ADC methodology utilizes monoclonal antibodies that target cancer cells with precision and directly transport cytotoxic substances to these targeted cellsThe introduction and positive outcomes of Loncastuximab Tesirine have prompted pharmaceutical firms to embark on ADC research and development endeavors as well. This has significantly impacted industry trends and treatment strategies as a whole.
02

Market Competitiveness

The emergence of loncastuximab tesirine is reshaping competitiveness within the oncology and hematology markets, as its targeted antibody-drug conjugate technology offers a novel treatment for relapsed or refractory B-cell malignancies. This transition pressures established pharmaceutical companies to enhance their pipelines with advanced therapies or explore alternative ADCs, bispecific antibodies, or CAR-T cell treatments to remain competitive. Associated industries such as biotech manufacturing, contract research organizations, and diagnostic labs are also impacted, as they adapt to increased demand for specialized production, clinical trial support, and biomarker-driven patient selection. For example, oncology labs now prioritize CD19 testing to identify eligible patients, while manufacturers invest in scalable ADC production technologies to meet growing market needs, reflecting the broader influence of loncastuximab tesirine on healthcare innovation and service delivery.